Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4 α
Conclusions: Our data revealed the significance of targeting PRMT5 activity in LCSC elimination and HCC differentiation, and proposed that DW14800 may represent a promising therapeutic agent for HCC in the clinic.
Source: Theranostics - Category: Molecular Biology Authors: Bai-Nan Zheng, Chen-Hong Ding, Shi-Jie Chen, Kongkai Zhu, Jingwei Shao, Jifeng Feng, Wen-Ping Xu, Ling-Yan Cai, Chang-Peng Zhu, Wenhu Duan, Jin Ding, Xin Zhang, Cheng Luo, Wei-Fen Xie Tags: Research Paper Source Type: research
More News: Alpha-1 Antitrypsin Deficiency | Cancer | Cancer & Oncology | Carcinoma | Genetics | Hepatocellular Carcinoma | Liver | Liver Cancer | Molecular Biology | Stem Cell Therapy | Stem Cells | Urology & Nephrology